FY2025 EPS Estimates for Alector Lifted by Cantor Fitzgerald

Alector, Inc. (NASDAQ:ALEC) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Alector in a report issued on Monday, November 10th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($1.50) for the year, up from their prior estimate of ($1.63). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($0.73) EPS.

Alector (NASDAQ:ALEC) last posted its earnings results on Thursday, November 6th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $3.26 million for the quarter, compared to analysts’ expectations of $3.49 million. Alector had a negative net margin of 156.03% and a negative return on equity of 123.02%. Alector has set its FY 2025 guidance at EPS.

Several other research firms also recently commented on ALEC. Mizuho set a $1.50 target price on Alector and gave the stock a “neutral” rating in a research report on Wednesday, October 22nd. Cowen cut Alector to a “hold” rating in a report on Wednesday, October 22nd. William Blair downgraded shares of Alector from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 22nd. Wall Street Zen cut shares of Alector from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. Finally, HC Wainwright cut their price target on shares of Alector from $10.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $3.00.

Alector Stock Up 3.8%

NASDAQ ALEC opened at $1.36 on Wednesday. Alector has a 1-year low of $0.87 and a 1-year high of $6.05. The company has a market capitalization of $148.44 million, a price-to-earnings ratio of -1.27 and a beta of 0.93. The stock’s 50 day moving average is $2.55 and its two-hundred day moving average is $1.93. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17.

Insider Buying and Selling at Alector

In related news, Director Paula Hammond sold 14,000 shares of the firm’s stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total transaction of $33,040.00. Following the sale, the director owned 74,909 shares of the company’s stock, valued at approximately $176,785.24. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 9.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alector

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALEC. Lexington Partners L.P. bought a new position in Alector during the 3rd quarter worth about $30,000. Pinegrove Venture Partners LLC bought a new stake in shares of Alector in the third quarter valued at about $30,000. Belvedere Trading LLC acquired a new position in shares of Alector during the third quarter worth about $31,000. HBK Sorce Advisory LLC bought a new stake in Alector in the 3rd quarter valued at approximately $34,000. Finally, Savant Capital LLC acquired a new stake in shares of Alector in the third quarter valued at approximately $35,000. 85.83% of the stock is owned by institutional investors and hedge funds.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.